Terrence W. Norchi, MD, our co-founder, serves as our President and Chief Executive Officer, and he is a director on our Board of Directors. Dr. Norchi has served in similar positions since co-founding ABS, our predecessor company in 2006. Prior to ABS, Dr. Norchi was portfolio manager of one of the world’s largest healthcare mutual funds and pharmaceutical analyst at Putnam Investments. Prior to that he served as the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management, and as a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.
Dr. Norchi earned an M.B.A. from the Massachusetts Institute of Technology, Sloan School of Management in 1996. Dr. Norchi earned an M.D. degree in 1990 from Northeast Ohio Medical University and completed his internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as the Chief Medical Resident.
Dr. Norchi brings to our Board of Directors and management team invaluable experience and knowledge of our core technology and proposed product candidates as a result of his first-hand experience with the development of that technology, having ushered it from the research laboratory to its current stage of development. He is a primary inventor on many of our patents. His investing experience as a former public company analyst and a portfolio manager provides further insights and value as the company advances toward commercialization.
Dr. Norchi serves on the Board of Advisors of the Boston Museum of Science.
Mr. Abrams has over 25 years of experience as a Chief Financial Officer to numerous public and private companies; principal investor; investment banker; merchant banker; strategic and financial advisor; and Board member. Mr. Abrams’ capabilities span a broad range of activities with a particular expertise in the areas of operational management, complex financial engineering, financial advisory, and capital markets strategy primarily for companies in the technology and healthcare sectors. Mr. Abrams graduated with an MBA with Honors from the Booth School of Business at the University of Chicago and received his BBA with Honors from the University of Massachusetts at Amherst as a William F. Field Alumni scholar, an award given annually to the top finance student in the class.
Mr. Yrigoyen has over 25 years of healthcare experience with a proven track record of driving business growth. Mr. Yrigoyen’s capabilities span a broad range of activities with expertise in the areas of new product launches, business process development, sales strategy, revenue generation and growth, metrics-driven performance management, and strategic partnership development. Most recently, Mr. Yrigoyen served as Vice President, Sales & Channel Distribution for Medela, Inc., a global medical device company. Prior to that, he served as General Manager and led both domestic and international commercial initiatives at Hollister, Inc., a worldwide manufacturer of healthcare products. Mr. Yrigoyen graduated with an MBA from the Kellogg School of Management at Northwestern University.
Mr. Wadsworth, an advisor to Arch as of 2019, has more than 30 years of experience leading innovation in scientific and engineering enterprises and driving value in public and private life science companies. He has commercialized over 100 medical device technology advancements in fields including wound healing, cancer drug delivery, ESRD, atherosclerotic disease, and orthopedics. Mr. Wadsworth has held executive leadership roles in medical device companies such as CR Bard (BD) and KCI (Acelity), and he has had responsibility for Commercialization, Research and Development, Quality and Regulatory organizations. He is also an entrepreneur, co-founder and COO of Metric Medical Devices, Inc. and is the recipient of two US patents in chemotherapy drug delivery.
Mr. Wadsworth has a BS in Biology from the University of New York at Albany and a Masters in Biomedical Engineering from Worcester Polytechnic Institute.
Mr. Dhillon joined our Board of Directors in July 2018. Mr. Dhillon brings over 15 years of global industry experience to Arch's Board with a wealth of knowledge and experience operationally in medical devices, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. Mr. Dhillon's business and management experience includes corporate finance, integration, intellectual property licensing, strategy implementation, mergers and acquisitions and collaborations with academic and other institutions. Strategic partnerships established by Mr. Dhillon include early and late stage deals with Merck and Pfizer. Mr. Dhillon co-founded OncoSec, a biotechnology company pioneering new technologies to stimulate the body's immune system to target and attack cancer. Prior to that, Mr. Dhillon served as Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), a DNA vaccine development company, from September 2003 until March 2011. Mr. Dhillon is also currently a director for Emerald Health Sciences, Inc. and Audit Committee Chair of Emerald Health Therapeutics, Inc. (TSXV: EMH) and Nemus Bioscience, Inc. (OTCQB: NMUS). Mr. Dhillon was recognized as one of the "Top 100 CEOs" by PharmaVoice in 2013, as "Most Admired CEO" by The San Diego Business Journal in 2016, and as a finalist for Ernst & Young's Annual "Entrepreneur of the Year." Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University.
Larry Hicks, an advisor to Arch, brings over 30 years of experience in medical devices. He started in field sales for ACMI, an endoscopy market leader, and subsequently joined Karl Storz Endoscopy and eventually led US Sales and Operations. In 2004, he rejoined ACMI to help lead a sales process (19x EBITDA in 2005) and then served as its President & CEO within Gyrus Group. Mr. Hicks returned to private equity as President & CEO of NeuroTherm (a Cortec Company), which he transformed from $10m revenue and 10 employees into a vertically integrated $50m Company with offices in Boston, London, Amsterdam and Dusseldorf. NeuroTherm was sold for a 5x return on invested capital in 5 years (noteworthy during the ‘07-‘12 economic period).
Mr. Hicks then spent two and a half years acquiring and integrating Z-MEDICA (maker of Combat Gauze Products) into the portfolio of DWHP, a private equity company with whom he
is a Limited Partner and advisor in Funds II-V and for whom he has served on various Boards. Z-Medica was acquired by Linden Capital Partners (6x return of capital to investors).
Mr. Hicks is currently the CEO of Healthcare Components Group, a global manufacturer of OEM and replacement parts used for the manufacture and repair of medical devices. He also serves as the Managing Partner at Drake Partners, LLC a boutique healthcare co-investment and operating company. Mr. Hicks received a BA from Fairfield University.
Dr. Fish joined our Board of Directors in January 2022. With over 30 years of experience in health care, life sciences, and biotechnology, Dr. Fish has a particular interest in cost-reducing strategies utilizing value-based reimbursement models. Dr. Fish is currently the CEO of the Greater Lawrence Family Health Centers, a nationally recognized Federally Qualified Health Center operating 9 clinical sites serving 70,000 patients.
Previously, Dr. Fish was CEO of Cellanyx, a cancer diagnostic company saving patients unnecessary surgery and complications by differentiating aggressive from indolent tumors. He has also worked as VP of Business Development at International Collagenesis, a tissue-engineering firm, as a securities analyst in the medical devices sector for Sanford Bernstein, as a healthcare consultant at The Boston Consulting Group, and as a solo practice physician. Dr. Fish is a Trustee Advisor of Beth Israel Deaconess Medical Center in Boston, where he previously chaired the Patient Care Committee and holds membership on the Patient Care Assessment and Quality Committee, and Medical Education Committee. He has served as Chairman of the Licensing Board for Dubai Health Care, as well as the Licensing Committee for the Board of Registration in Medicine for the Commonwealth of Massachusetts. Dr. Fish is currently a member of the Board of Directors of Etiometry and of the Altarum Institute.
Dr. Fish is Board Certified in Internal Medicine, holds an MBA from the Yale School of Management, an MD from the Yale School of Medicine, and a bachelor's degree in biochemistry from Harvard University.